Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Open-label, Single-arm Study to Evaluate Efficacy and Safety of FIX Gene Transfer With PF-06838435 (rAAV-Spark100-hFIX-R338L) in Adult Male Participants With Moderately Severe to Severe Hemophilia B (FIX:C ≤2%) (BeneGene-2)

NCT03861273 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03861273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03861273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Open-label, Single-arm Study to Evaluate Efficacy and Safety of FIX Gene Transfer With PF-06838435 (rAAV-Spark100-hFIX-R338L) in Adult Male Participants With Moderately Severe to Severe Hemophilia B (FIX:C ≤2%) (BeneGene-2)
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 29, 2019
Completion date
February 25, 2031
Enrollment
51 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia b